Clonmel Healthcare has launched Bosutinib Clonmel 100mg, 500mg film-coated tablets for the treatment of adult patients with chronic phase Philadelphia chromosome-positive myelogenous leukaemia. It is also indicated for patients previously treated with tyrosine kinase inhibitors, where other treatment options are not suitable. Full prescribing information can be found on their website or requested directly. The medicinal product requires a restricted medical prescription. For additional information, individuals are encouraged to contact Clonmel Healthcare at 01 620 4000.
Source link
Bosutinib Clonmel launched
